



## Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023

April 6, 2023

REDWOOD CITY, Calif., April 06, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the company and its collaborators will present preclinical data at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023 being held April 14-19, 2023, in Orlando, Florida.

Details of the planned presentations are listed below:

### **Revolution Medicines Oral Presentations:**

**Title:** [Discovery of RMC-6291, a tri-complex KRAS<sup>G12C</sup>\(ON\) inhibitor](#)  
**Presenter:** Jim Cregg, Ph.D.  
**Abstract Number:** ND07  
**Session:** New Drugs on the Horizon: Part 2  
**Date/Time:** 3:45 – 4:00 p.m. Eastern on April 16, 2023

**Title:** [RMC-9805, a first-in-class, mutant-selective, covalent and orally bioavailable KRAS<sup>G12D</sup>\(ON\) inhibitor, promotes cancer-associated neoantigen recognition and synergizes with immunotherapy in preclinical models](#)  
**Presenter:** Marie Menard, Ph.D.  
**Abstract Number:** 3475  
**Session:** Immune Checkpoints at Tumor Beds  
**Date/Time:** 3:37 – 3:52 p.m. Eastern on April 17, 2023

### **Revolution Medicines Poster Presentations:**

**Title:** [RMC-9805, a first-in-class, mutant-selective, covalent and oral KRAS<sup>G12D</sup>\(ON\) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRAS<sup>G12D</sup> cancers](#)  
**Presenter:** Lingyan Jiang, Ph.D.  
**Abstract Number:** 526/26  
**Session:** Novel Antitumor Agents 2  
**Date/Time:** 1:30 – 5:00 p.m. Eastern on April 16, 2023

**Title:** [RMC-0708 \(RM-046\), a first-in-class, mutant-selective and oral KRAS<sup>Q61H</sup>\(ON\) inhibitor that drives tumor regression in preclinical models and validates KRAS<sup>Q61H</sup> as a therapeutic target](#)  
**Presenter:** Yu C. Yang, Ph.D.  
**Abstract Number:** 1598/21  
**Session:** New Therapeutic Targeted Agents  
**Date/Time:** 9:00 a.m. – 12:30 p.m. Eastern on April 17, 2023

### **Collaborator Oral Presentation:**

**Title:** [Combining KRAS<sup>G12C</sup>\(ON\) inhibition with SHP2 and immune checkpoint blockade to enhance anti-tumor immunity and overcome development of resistance in lung cancer](#)  
**Abstract Number:** 5733  
**Session:** New Tricks for Known Targets: Novel Approaches to Inhibit Oncogenic Signaling  
**Presentation Time:** 2:37 – 2:52 p.m. Eastern on April 18, 2023

### **Collaborator Poster Presentations:**

**Title:** [Bi-steric mTORC1-selective inhibitors activate 4EBP1, suppress MYC, restore anti-tumor immunity, and cooperate with immune checkpoint inhibition to elicit tumor regression](#)

**Abstract Number:** LB015/7  
**Session:** Late-Breaking Research: Experimental and Molecular Therapeutics 1  
**Presentation Time:** 1:30 – 5:00 p.m. Eastern on April 16, 2023

**Title:** [Preclinical evaluation of RM-042, an orally bioavailable inhibitor of GTP-RAS, in models of pancreatic ductal adenocarcinoma](#)  
**Abstract Number:** 1725/22  
**Session:** Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2  
**Date/Time:** 9:00 a.m. – 12:30 p.m. Eastern on April 17, 2023

**Title:** [Bi-steric mTORC1 inhibitors are superior to rapamycin and induce apoptotic cell death in tumor models with hyperactivated mTORC1](#)  
**Abstract Number:** 4859/2  
**Session:** Anticancer Approaches Targeting Signal Transduction Pathways  
**Presentation Time:** 1:30 – 5:00 p.m. Eastern on April 18, 2023

Additional information on the AACR Annual Meeting 2023 is available through the AACR website at: <https://www.aacr.org/meeting/aacr-annual-meeting-2023/>

#### **About Revolution Medicines, Inc.**

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RAS<sup>MULTI</sup>) and RMC-6291 (KRAS<sup>G12C</sup>) are currently in clinical development. Additional RAS(ON) Inhibitors in the company's pipeline include RMC-9805 (KRAS<sup>G12D</sup>) and RMC-0708 (KRAS<sup>Q61H</sup>), both of which are currently in IND-enabling development, RMC-8839 (KRAS<sup>G13C</sup>), and additional compounds targeting other RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).

Contacts: For Investors & Media: Erin Graves 650-779-0136 [egraves@revmed.com](mailto:egraves@revmed.com)